Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

THE CALCIUM-SENSING RECEPTOR (CAS RECEPTOR) PLAYS A PIVOTAL ROLE IN EXTRACELLULAR CALCIUM HOMEOSTASIS AND GERMLINE LOSS- AND GAIN-OF-FUNCTION MUTATIONS CAUSE FAMILIAL HYPOCALCIURIC HYPERCALCAEMIA (FHH) AND AUTOSOMAL DOMINANT HYPOCALCAEMIA (ADH), RESPECTIVELY. CAS RECEPTOR SIGNAL TRANSDUCTION IN THE PARATHYROID GLANDS IS LIKELY REGULATED BY G-PROTEIN SUBUNIT Α11 (GΑ11) AND ADAPTOR-RELATED PROTEIN COMPLEX-2 SIGMA SUBUNIT (AP2Σ), AND RECENT STUDIES HAVE IDENTIFIED GERMLINE MUTATIONS OF THESE PROTEINS AS A CAUSE OF FHH AND/OR ADH. CALCIMIMETICS AND CALCILYTICS ARE POSITIVE AND NEGATIVE ALLOSTERIC MODULATORS OF THE CAS RECEPTOR THAT HAVE POTENTIAL EFFICACY FOR SYMPTOMATIC FORMS OF FHH AND ADH. CELLULAR STUDIES HAVE DEMONSTRATED THAT THESE COMPOUNDS CORRECT SIGNALLING AND/OR TRAFFICKING DEFECTS CAUSED BY MUTANT CAS RECEPTOR, GΑ11 OR AP2Σ PROTEINS. MOREOVER, MOUSE MODEL STUDIES INDICATE THAT CALCILYTICS CAN RECTIFY THE HYPOCALCAEMIA AND HYPERCALCIURIA ASSOCIATED WITH ADH, AND PATIENT-BASED STUDIES REVEAL CALCIMIMETICS TO AMELIORATE SYMPTOMATIC HYPERCALCAEMIA CAUSED BY FHH. THUS, CALCIMIMETICS AND CALCILYTICS REPRESENT TARGETED THERAPIES FOR INHERITED DISORDERS OF THE CAS RECEPTOR SIGNALLING PATHWAY.

Original publication

DOI

10.1111/bph.14086

Type

Journal article

Journal

Br J Pharmacol

Publication Date

11/11/2017